Bavarian Nordic AS logo

Bavarian Nordic AS

BVNRY · OTC · Pharmaceuticals, Biotech · Founded 1992

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer.

Current Price
$12.07
Market Cap
$2.8B
Return Since Last Split
-1%
Last Split
Jan 20, 2016
Total Splits
1
Cumulative Multiple
3×

What If You Bought BVNRY Earlier?

Investment
Purchase Date (Before Split)
Worth Today
$3,621
300 shares · 3×

Estimate based on split history only. Excludes dividends, fees, taxes, and intraday movement.

Stock Split History

Newest split first. Cumulative multiple = compounded growth within the displayed company lineage.

Split DatePrice BeforeRatioSplit MultipleCumulative
Jan 20, 2016—3-for-13×3×

Bavarian Nordic AS Market Cap Timeline

Validated annual market-cap history is available from 2002. Split markers cover 1 current-security split. Filled dots have market-cap data for that year; hollow dots mark split years outside market-cap source coverage.

Frequently Asked Questions

Bavarian Nordic AS's latest record in the split calendar is a 3-for-1 forward split effective 2016-01-20.
Stay in the loop

Never Miss a Stock Split Again

Get personalized stock split alerts. Choose what you receive and how often.

Your email is securely stored. We’ll only contact you about updates you choose. Unsubscribe anytime.